According to the IDF Diabetes Atlas, there are approximately 537 million diabetes patients worldwide, over 90% of whom have type 2 diabetes. Nearly half of these individuals have not yet been diagnosed. It is estimated that the number will rise to 643 million by 2030, and could reach as high as 783 million by 2045.
As for the diabetes situation in Thailand, data from the Ministry of Public Health statistics report shows a continuous increase in diabetes incidence. In 2023, there were 300,000 new patients per year, while the cumulative number of diabetes patients in 2022 reached 3.3 million, an increase of 150,000 from 2021. Screening for new patients in 2023 revealed that 5 million people aged 35 and older have not been screened for diabetes, out of a nationwide target of 22 million.
Related news:
“Diabetes” is a significant health problem for Thais that is quite dangerous.
The pharmaceutical industry is growing rapidly; 5.2 million Thais are diagnosed with diabetes.
Current Diabetes Treatment Guidelines
Professor Chaiyan Dirojanawong, President of the Thai Endocrine Society, revealed that diabetes has always been a major issue for Thais, especially in an era where people’s lifestyles have become more convenient, leading to an increasing number of diabetes patients each year.
Diabetes is caused by the body’s inability to transport glucose into cells due to a deficiency of the hormone insulin and/or insulin resistance, resulting in elevated blood sugar levels. Maintaining blood sugar levels close to normal in diabetes patients is crucial to reduce the risk of various complications such as kidney failure, blindness, and cardiovascular diseases.
Current diabetes care has various methods, including dietary control, exercise, and the use of blood sugar-lowering medications. These methods are important for helping to keep blood sugar levels within normal ranges, but they must also be adjusted to suit individual patients, as they have different blood sugar levels and comorbid factors. Newer medications are now available to ensure effective diabetes management.
Innovative Diabetes Medications
Initially, diabetes treatment involved the use of injected insulin and oral medications from the sulfonylurea group to lower blood sugar levels. The major drawbacks of these two drug groups are the risk of hypoglycemia and weight gain following treatment. Additionally, there is metformin, which does not cause hypoglycemia and does not lead to weight gain. Currently, innovative new drugs have been continuously developed for diabetes treatment, especially in the oral medication category, which is an option for patients who are not comfortable with injections. These include:
1. GLP-1 Receptor Agonists
Medications in the GLP-1 Receptor Agonists group work by stimulating GLP-1 receptors, which are hormones naturally produced in the intestines. This significantly reduces blood sugar levels, as these drugs only act when blood sugar levels are high. Therefore, they do not increase the risk of hypoglycemic episodes. Additionally, they can help with weight loss, which is a significant advantage for diabetes patients who often struggle with obesity.
This drug group also has benefits in reducing the risk of cardiovascular diseases, making GLP-1 Receptor Agonists an interesting choice, especially for patients at high risk for heart and vascular diseases. Recent data also indicate that they can slow kidney deterioration in diabetes patients.
Recently, GLP-1 Receptor Agonists have been developed from traditional injectable forms to oral forms that have comparable efficacy, representing a significant advancement that demonstrates new innovations that provide patients with more convenient treatment options.
2. SGLT2 Inhibitors
SGLT2 Inhibitors play a role in controlling blood sugar levels by inhibiting the reabsorption of sugar in the kidneys, allowing the body to excrete sugar via urine. These drugs do not cause hypoglycemia and also have the advantage of reducing the risk of cardiovascular diseases and slowing kidney deterioration. They are considered another option for diabetes management.
3. DPP-4 Inhibitors
DPP-4 Inhibitors work by inhibiting the enzyme DPP-4, which is responsible for breaking down the GLP-1 hormone in the body. These drugs have the advantage of not increasing the risk of hypoglycemia, but they do not affect body weight and have no direct effect on reducing the risk of heart and kidney diseases.
Research Advances in Thailand
Clinical research is extremely important for doctors and patients, particularly in the context of Thailand. Clinical research tailored to the Thai population not only helps to understand the needs and health issues of patients but also develops more suitable and effective treatment guidelines.
Current innovations in diabetes medications in Thailand have resulted in enhanced patient care by increasing treatment options that meet individual needs, marking a significant advancement that should be continuously supported and developed. However, these positive developments alone may not be sufficient to prevent diabetes.
Maintaining a balanced diet and regular exercise remains a primary strategy for effectively preventing and managing diabetes. Understanding the types and amounts of food consumed and modifying lifestyle habits can also reduce the risk of complications from diabetes.
Nonetheless, new innovations in diabetes medications combined with proper dietary consumption and regular exercise are key to effectively managing diabetes in Thailand.
Future Trends in Diabetes Management and Treatment Innovations
The global diabetes epidemic is a growing concern, with an estimated 537 million individuals currently living with the disease, predominantly type 2 diabetes. Reports indicate that this number could escalate to 643 million by 2030 and potentially reach 783 million by 2045. In Thailand alone, the rise in diabetes cases is alarming, with 3.3 million prevalent cases in 2022, accompanied by a new influx of 300,000 patients annually.
Innovation in Diabetes Treatment
As the prevalence of diabetes continues to surge in Thailand and around the world, the pharmaceutical industry is responding with novel treatment options. These innovations are not limited to traditional medication; new classes of oral antidiabetic agents, like GLP-1 receptor agonists and SGLT2 inhibitors, are making waves. GLP-1 receptor agonists stand out for their dual capability to lower blood sugar and facilitate weight loss, paving the way for a more holistic approach to diabetes care.
Furthermore, the development of oral formulations of these medications offers a significant advantage over injected options, increasing patient adherence and comfort. The convenience of taking medication orally can lead to better management of the disease and potentially reduce associated complications such as heart disease and kidney damage.
Clinical Research and Personalized Care
Ongoing clinical research tailored to the Thai population is critical. By understanding localized health challenges and requirements, the medical community can craft more effective treatment protocols. This is particularly pertinent as healthcare strategies evolve to incorporate personalized medicine, where treatment plans are customized based on individual patient profiles, including their genetic predispositions and lifestyle choices.
Holistic Approaches: Diet and Lifestyle
While medication plays a vital role in diabetes management, lifestyle modifications remain at the forefront of preventative strategies. Emphasizing healthy eating habits and regular physical activity is essential. It’s crucial for patients to engage in educational programs that illuminate their nutritional choices and encourage positive behavior modifications.
Looking forward, a collaborative effort among healthcare providers, researchers, and patients is essential to tackle the diabetes crisis effectively. Innovations in medication will need to be accompanied by public health initiatives that promote awareness and healthy living to truly advance diabetes outcomes in both Thailand and globally.